Tin tức & Cập nhật

The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.

Tapering the dose of vancomycin over 2 weeks following initial 14-day therapy appears to work better than the 14-day fixed dosing at reducing the recurrence of Clostridioides difficile infection (CDI), as shown in the TAPER-V trial.